EMA Nods pre-filled syringe For administration of Eylea 8 mg in EU

The pre-filled syringe for administering Eylea 8 mg (114.3 mg/ml solution for injection) has been authorized by the European Medicines Agency (EMA) for use in the European Union. The recently introduced pre-filled syringe OcuClick offers ophthalmologists a convenient and easy method to precisely administer the 70-microliter dose of Eylea 8 mg for treating neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) as approved. Germany will be among the initial markets to introduce the pre-filled syringe.

“We are thrilled about the introduction of the pre-filled syringe for Eylea 8 mg, as it represents a significant advancement in administering an eye injection. This simple, easy, and accurate application method will greatly benefit ophthalmologists and patients, allowing for fast and precise treatment,” said University Professor Dr. med Oliver Zeitz, senior consultant and site manager of the department of ophthalmology at the Charité Campus Benjamin Franklin, Berlin, Germany.

“As a leader in ophthalmology we relentlessly strive for customer-oriented solutions,” said Christine Roth, executive vice president, global product strategy and commercialization, and Member of the Pharmaceuticals Leadership Team at Bayer. “OcuClick offers the doctor excellent control, precision, and simplicity for the administration of Eylea 8 mg. This innovative ophthalmic syringe, combined with the Eylea 8 mg solution approved for extended treatment intervals of up to five months in appropriate patients, shows how our innovation can directly benefit patients.”